OnQuality Pharmaceuticals is pioneering the field of targeted supportive cancer care. Our lead compound is an oncodermatology hand and foot ointment called OQL011, which is for the treatment of Hand-Foot Skin Reaction. It is being studied in a phase 2 clinical trial that is currently enrolling. We also have two promising assets that are currently in the pre-clinical stage and will enter clinical trials in the near future. Additionally, we have two promising assets that are in the early discovery stage targeting oncogastroenterology conditions.
VEGFR Inhibitor-induced hand-foot skin reaction